Alternatives to Orthogon Therapeutics

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

A global leader in clinical pharmacology and bioanalytical sciences.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

Pioneering vision restoration therapies for severe retinal degenerations.

Developing oral small molecule medicines for immunological and chronic diseases.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Immunotherapy company targeting oncology and autoimmune diseases.

Clinical-stage immunotherapy company developing novel treatments for cancer.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing novel male contraceptives.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Advancing targeted alpha therapies.

A biopharmaceutical company focused on drug discovery and development.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.

Biopharmaceutical company developing best-in-class medicines for autoimmune and rare diseases, with a focus on thyroid eye disease.

Biotechnology company developing novel protein-based antimicrobial therapeutics.

Clinical-stage biotech company developing transformative cytokine therapies.

Accelerating medicine for the people who need it, prescribe it, and create it.

Discovering and developing first-in-class antibody therapeutics by identifying protective antibodies from disease-resilient individuals.

Developing novel therapeutics for inflammatory and hypoxic diseases.

Venture philanthropy organization accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD).

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Biotechnology company developing novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Developing novel immunotherapies and diagnostics for cancer.

Developing gene editing therapies to lower cholesterol.

Developing highly targeted, small molecule medicines.

Developing ultrasound-mediated nonviral genetic medicines.

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.